Boditech Med (A206640) Stock Overview
Offers instruments and diagnostic reagents in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
A206640 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Boditech Med Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩13,220.00 |
| 52 Week High | ₩18,670.00 |
| 52 Week Low | ₩12,940.00 |
| Beta | 0.23 |
| 1 Month Change | 0.15% |
| 3 Month Change | -9.08% |
| 1 Year Change | -17.63% |
| 3 Year Change | 28.35% |
| 5 Year Change | -50.76% |
| Change since IPO | -76.24% |
Recent News & Updates
Recent updates
Boditech Med (KOSDAQ:206640) Will Pay A Smaller Dividend Than Last Year
Feb 24
Risks Still Elevated At These Prices As Boditech Med Inc. (KOSDAQ:206640) Shares Dive 26%
Oct 14Boditech Med (KOSDAQ:206640) Has More To Do To Multiply In Value Going Forward
Oct 11Does Boditech Med (KOSDAQ:206640) Have A Healthy Balance Sheet?
Sep 13Investor Optimism Abounds Boditech Med Inc. (KOSDAQ:206640) But Growth Is Lacking
Jul 12Boditech Med Inc. (KOSDAQ:206640) Shares Fly 49% But Investors Aren't Buying For Growth
Apr 16Here's Why I Think Boditech Med (KOSDAQ:206640) Might Deserve Your Attention Today
Apr 13Could The Market Be Wrong About Boditech Med Inc. (KOSDAQ:206640) Given Its Attractive Financial Prospects?
Mar 01Boditech Med (KOSDAQ:206640) Seems To Use Debt Rather Sparingly
Jan 18
Here's Why I Think Boditech Med (KOSDAQ:206640) Is An Interesting Stock
Dec 28Did Business Growth Power Boditech Med's (KOSDAQ:206640) Share Price Gain of 193%?
Dec 08Boditech Med Inc. (KOSDAQ:206640) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 18Shareholder Returns
| A206640 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -4.1% | -0.6% | 5.3% |
| 1Y | -17.6% | 5.9% | 73.0% |
Return vs Industry: A206640 underperformed the KR Medical Equipment industry which returned 5.9% over the past year.
Return vs Market: A206640 underperformed the KR Market which returned 73% over the past year.
Price Volatility
| A206640 volatility | |
|---|---|
| A206640 Average Weekly Movement | 3.0% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.6% |
Stable Share Price: A206640 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A206640's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 515 | n/a | www.boditech.co.kr/en |
Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testing for various parameters; ExAmplar, a compact real time PCR that detects virus/bacteria quantitatively or qualitatively using ready-to-use cartridges; ichroma-50, an automated immunoassay system with high-throughput; Hemochroma PLUS, a handheld device that can run tests for anemia; portable analyzers ichroma M3 and ichroma M2; and NuActor, an automated nucleic acid extraction system. It also provides compact immunoassay analyzers, including AFIAS-1, AFIAS-3, AFIAS-6, and AFIAS-10; cardiac reagents; cancer reagents; COVID-19 reagents; diagnostic reagents; reagents for hormones, infections, autoimmune, organ functions, molecular diagnostics, therapeutic drug monitoring, and other test items.
Boditech Med Inc. Fundamentals Summary
| A206640 fundamental statistics | |
|---|---|
| Market cap | ₩287.97b |
| Earnings (TTM) | ₩27.23b |
| Revenue (TTM) | ₩151.75b |
Is A206640 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A206640 income statement (TTM) | |
|---|---|
| Revenue | ₩151.75b |
| Cost of Revenue | ₩63.83b |
| Gross Profit | ₩87.92b |
| Other Expenses | ₩60.70b |
| Earnings | ₩27.23b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.25k |
| Gross Margin | 57.94% |
| Net Profit Margin | 17.94% |
| Debt/Equity Ratio | 6.5% |
How did A206640 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/09 01:55 |
| End of Day Share Price | 2025/12/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Boditech Med Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jaehoon Choi | Korea Investment & Securities Co., Ltd. |
| Seung-Ho Lee | Samsung Securities Co. Ltd. |
| Dongguen Kang | Yuanta Securities Korea Co., Ltd. |